NEWS

NOVEL THERAPY FOR IDIOPATHIC PULMONARY FIBROSIS (IPF)

Patients with idiopathic pulmonary fibrosis treated with a recombinant human pentraxin 2 protein exhibited sustained reductions in decline of FVC and 6-minute walking distance at 76 weeks, according to data presented at the American Thoracic Society International Conference and simultaneously published in The Lancet Respiratory Medicine.

In an accompanying editorial, Demosthenes Bouros, MD, PhD, FERS, FCCP, FAPSR, head of the interstitial lung disease unit of the National and Kapodistrian University of Athens in Greece, and colleagues highlighted the need for continued data on this novel agent.